The (Eternal) Debate on Microwave Ablation
Hepatocellular carcinoma
liver cancer
microwave ablation
radiofrequency ablation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
24
06
2020
revised:
14
07
2020
accepted:
15
07
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
While percutaneous radiofrequency ablation (RFA) is considered the standard ablative modality for the treatment of early-stage hepatocellular carcinoma (HCC), percutaneous microwave ablation (MWA) is being increasingly used in recent years. We performed a systematic review and meta-analysis to compare percutaneous MWA versus percutaneous RFA in BCLC-A HCC across randomized controlled trials (RCTs). Eligible studies included RCTs assessing MWA versus RFA in BCLC-A HCC. Outcomes of interest included: complete ablation (CA) rate, local recurrence (LR) rate, 1-year overall survival (OS) rate, 3-year OS rate and major complications rate. We retrieved all the relevant RCTs through PubMed/Medline, Cochrane library and EMBASE; five eligible studies involving a total of 794 patients (MWA: 409; RFA: 385) and 1008 nodules of HCC (MWA: 519; RFA: 489) were included in our analysis. No significant differences were found between MWA and RFA regarding CA, LR, 3-year OS and major complications rate. Regarding 1-year OS, a higher rate was observed in the MWA group. MWA and RFA are effective and safe techniques in early stage, BCLC-A, HCCMWA resulted in better 1-year OS, although this benefit was not confirmed in the 3-year analysis.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
While percutaneous radiofrequency ablation (RFA) is considered the standard ablative modality for the treatment of early-stage hepatocellular carcinoma (HCC), percutaneous microwave ablation (MWA) is being increasingly used in recent years. We performed a systematic review and meta-analysis to compare percutaneous MWA versus percutaneous RFA in BCLC-A HCC across randomized controlled trials (RCTs).
PATIENTS AND METHODS
METHODS
Eligible studies included RCTs assessing MWA versus RFA in BCLC-A HCC. Outcomes of interest included: complete ablation (CA) rate, local recurrence (LR) rate, 1-year overall survival (OS) rate, 3-year OS rate and major complications rate.
RESULTS
RESULTS
We retrieved all the relevant RCTs through PubMed/Medline, Cochrane library and EMBASE; five eligible studies involving a total of 794 patients (MWA: 409; RFA: 385) and 1008 nodules of HCC (MWA: 519; RFA: 489) were included in our analysis. No significant differences were found between MWA and RFA regarding CA, LR, 3-year OS and major complications rate. Regarding 1-year OS, a higher rate was observed in the MWA group.
CONCLUSION
CONCLUSIONS
MWA and RFA are effective and safe techniques in early stage, BCLC-A, HCCMWA resulted in better 1-year OS, although this benefit was not confirmed in the 3-year analysis.
Identifiants
pubmed: 33144450
pii: 34/6/3421
doi: 10.21873/invivo.12181
pmc: PMC7811655
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3421-3429Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Abdom Radiol (NY). 2018 Jan;43(1):13-25
pubmed: 28647765
World J Gastroenterol. 2019 Aug 28;25(32):4614-4628
pubmed: 31528090
Hepatol Int. 2019 Mar;13(2):125-137
pubmed: 30600478
J Oncol Pract. 2017 Jun;13(6):368-369
pubmed: 28605613
J Hepatol. 2010 Mar;52(3):380-8
pubmed: 20149473
Clin Radiol. 2013 Jun;68(6):608-15
pubmed: 23399463
Br J Surg. 2011 Sep;98(9):1210-24
pubmed: 21766289
Lancet Gastroenterol Hepatol. 2018 May;3(5):317-325
pubmed: 29503247
Eur J Gastroenterol Hepatol. 2016 Oct;28(10):1198-203
pubmed: 27362551
Hepatobiliary Surg Nutr. 2014 Oct;3(5):317-23
pubmed: 25392844
Int J Surg. 2010;8(5):336-41
pubmed: 20171303
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):897-908
pubmed: 25260316
J Gastrointest Oncol. 2019 Jun;10(3):562-571
pubmed: 31183208
Abdom Radiol (NY). 2016 Apr;41(4):650-8
pubmed: 26880177
Korean J Radiol. 2018 Jul-Aug;19(4):545-559
pubmed: 29962861
In Vivo. 2020 Mar-Apr;34(2):479-488
pubmed: 32111744
Gastroenterology. 2016 Apr;150(4):835-53
pubmed: 26795574
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
World J Surg Oncol. 2019 Jun 10;17(1):98
pubmed: 31182102
Radiographics. 2014 Sep-Oct;34(5):1344-62
pubmed: 25208284
Sci Rep. 2018 Jul 3;8(1):9997
pubmed: 29968763
Br J Surg. 2017 Nov;104(12):1704-1712
pubmed: 28745399
Int J Hyperthermia. 2019;36(1):264-272
pubmed: 30676100
Surg Endosc. 2014 Dec;28(12):3429-34
pubmed: 24935203
World J Hepatol. 2016 Jun 18;8(17):703-15
pubmed: 27330679
World J Hepatol. 2015 Feb 27;7(2):245-52
pubmed: 25729479
Liver Cancer. 2019 Oct;8(5):326-340
pubmed: 31768343
Clin Radiol. 2017 Aug;72(8):626-635
pubmed: 28258743
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
J Gastroenterol Hepatol. 2016 Feb;31(2):294-301
pubmed: 26114968
World J Surg Oncol. 2017 Jul 10;15(1):126
pubmed: 28693505
Int J Hyperthermia. 2016 May;32(3):339-44
pubmed: 26794414
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
J Hepatol. 2013 Jul;59(1):89-97
pubmed: 23523578
Anticancer Res. 2020 Feb;40(2):597-608
pubmed: 32014900
Int J Hyperthermia. 2020;37(1):479-485
pubmed: 32396398
Radiology. 2002 May;223(2):331-7
pubmed: 11997534
Cardiovasc Intervent Radiol. 2014 Jun;37(3):723-9
pubmed: 24196263
Liver Transpl. 2019 Jan;25(1):88-97
pubmed: 30415500
Gut. 2017 Jun;66(6):1172-1173
pubmed: 27884919